

Takeda Rare Immunology

With decades of experience advancing medicines in allergy and immunology, and our demonstrated ability to engage with this unique patient and provider community, Takeda is **distinctly positioned to prioritize the evolving needs of rare immunology patients.**

There are **more than 7,000** types of rare diseases, including rare immunological conditions, that have a profound impact on patients' lives.¹

By helping to address significant unmet needs for individuals living with various rare angioedema, immune-mediated and primary immune deficiency diseases through our existing medicines and clinical development pipeline, our aim is to help **personalize care at every step of the journey.**

TAKEDA'S MARKETED RARE PRODUCTS AND ASSETS AIM TO SUPPORT SEVERAL DISEASE AREAS

Hereditary Angioedema (HAE)

A rare and potentially life-threatening genetic condition that involves recurrent attacks of swelling (angioedema) in various parts of the body.²

Primary Immunodeficiency (PI)

An umbrella term used to describe more than 485 rare, genetic or inherited, chronic disorders that disrupt the body's immune system from functioning properly.³

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

A rare, acquired, immune-mediated neuromuscular disorder affecting the peripheral nervous system.^{4,5}

Eosinophilic Esophagitis (EoE)

A chronic inflammatory disease that occurs in the esophagus due to a buildup of eosinophils and other inflammatory cells.⁶

Multifocal Motor Neuropathy (MMN)

A rare neuromuscular disorder where focal areas of multiple motor nerves are attacked by one's own immune system.⁷

Alpha-1 Antitrypsin Deficiency (AATD)

A genetic condition that can cause damage to the lungs and/or the liver.⁸

WE AIM TO EMPOWER THE RARE IMMUNOLOGY COMMUNITY

Takeda strives to bring a brighter future for patients, their caregivers and health care professionals by **creating equitable access to care** and **enabling a faster diagnostic journey.**

We're prioritizing, listening and understanding patients' unmet needs to address health inequities and improve treatment outcomes. Through **impactful research, meaningful collaborations** and **innovative technology advancements**, we're working to reduce time to diagnosis and improve access to care, particularly in rural and underserved areas.

References: ¹The Lancet Global Health. *The landscape for rare diseases in 2024*. Accessed October 2024. ²HAE International (HAEI). *What is HAE?* Accessed October 2024. ³Immune Deficiency Foundation. *About Primary Immunodeficiencies*. Accessed October 2024. ⁴Dalakas MC. *Nat Rev Neurol*. 2011;7(9):507-17 ⁵GBS|CIDP Foundation International. *Voice of the Patient Report* (2022). Accessed October 2024. ⁶Furuta GT, Katzka DA. *N Engl J Med*. 2015;373(17):1640-1648. ⁷GBS|CIDP Foundation International. *What is MMN?* Accessed October 2024. ⁸Alpha-1 Foundation. *What is Alpha-1?* Accessed October 2024.

C-ANPROM/INT/NON/0003 October 2024. ©2024 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited.

